| Name | Title | Contact Details |
|---|
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.
The Advisory Board is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clinical Trials of Texas is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Technogym is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Celleration Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Eden Prairie, MN. To find more information about Celleration Inc, please visit www.celleration.com